Last updated: 9 May 2023 at 4:18pm EST

Bastiano Sanna Net Worth




The estimated Net Worth of Bastiano Sanna is at least $25.7 million dollars as of 5 May 2023. Bastiano Sanna owns over 3,272 units of Vertex Pharmaceuticals stock worth over $15,209,720 and over the last 4 years Bastiano sold VRTX stock worth over $10,535,018.

Bastiano Sanna VRTX stock SEC Form 4 insiders trading

Bastiano has made over 21 trades of the Vertex Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently Bastiano sold 3,272 units of VRTX stock worth $1,145,200 on 5 May 2023.

The largest trade Bastiano's ever made was selling 7,567 units of Vertex Pharmaceuticals stock on 12 April 2023 worth over $2,472,139. On average, Bastiano trades about 1,009 units every 23 days since 2021. As of 5 May 2023 Bastiano still owns at least 32,038 units of Vertex Pharmaceuticals stock.

You can see the complete history of Bastiano Sanna stock trades at the bottom of the page.



What's Bastiano Sanna's mailing address?

Bastiano's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.

Insiders trading at Vertex Pharmaceuticals

Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden et Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.



What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.



Complete history of Bastiano Sanna stock trades at Vertex Pharmaceuticals

Initié
Trans.
Transaction
Prix ​​total
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $1,145,200
5 May 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $1,544,176
2 May 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $2,472,139
12 Apr 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $164,853
4 Apr 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $825,420
16 Mar 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $655,151
14 Feb 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $33,944
10 Feb 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $34,450
31 Jan 2023
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $100,045
1 Nov 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $537,855
18 Oct 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $11,377
16 May 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $9,903
4 May 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $82,931
2 May 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $154,937
7 Apr 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $1,021,023
4 Apr 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $530,627
17 Mar 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $261,019
1 Feb 2022
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $24,230
17 May 2021
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $209,693
30 Apr 2021
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $361,040
5 Apr 2021
Bastiano Sanna
Vice-président exécutif, Cell et Genetic Therapies
Vente $355,004
11 Feb 2021


Vertex Pharmaceuticals executives and stock owners

Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: